Cascadian Therapeutics (CASC)

[aries4747]

Why Franklin Resources Inc Reported Big Oncothyreon Inc Position?

http://www.fdanewsalert.com/why-franklin-resources-inc-reported-big-oncothyreon-inc-position/8511800/

Franklin Resources Inc filed with the SEC SC 13G form for Oncothyreon Inc. The form can be accessed here: 000003877716000406. As reported in Franklin Resources Inc’s form, the filler as of late owns 7.3% or 6,899,600 shares of the Health Care–company.

Oncothyreon Inc stake is a new one for the for this institutional investor and it was filed because of activity on December 31, 2015. We feel this shows Franklin Resources Inc’s positive view for the stock.


Why Franklin Resources Inc Reported Big Oncothyreon Inc Position?
Passive and Active Investment News

February 14, 2016 By Patrick Sproles
Franklin Resources Inc filed with the SEC SC 13G form for Oncothyreon Inc. The form can be accessed here: 000003877716000406. As reported in Franklin Resources Inc’s form, the filler as of late owns 7.3% or 6,899,600 shares of the Health Care–company.

Oncothyreon Inc stake is a new one for the for this institutional investor and it was filed because of activity on December 31, 2015. We feel this shows Franklin Resources Inc’s positive view for the stock.
Oncothyreon Inc Institutional Sentiment

Latest Security and Exchange filings show 87 investors own Oncothyreon Inc. The institutional ownership in Q3 2015 is high, at 58.14% of the outstanding shares. This is decreased by 1123001 the total institutional shares. 55193956 were the shares owned by these institutional investors. In total 9 funds opened new Oncothyreon Inc stakes, 21 increased stakes. There were 22 that closed positions and 42 reduced them.

Jeremy Green Redmile Group Llc is an institutional investor bullish on Oncothyreon Inc, owning 3614990 shares as of Q3 2015 for 0.21% of its portfolio. Perkins Capital Management Inc owns 390650 shares or 1.19% of its portfolio. CA Venbio Select Advisor Llc have 3.92% of their stock portfolio for 5506618 shares. Further, Ecor1 Capital Llc reported stake worth 1.18% of its US stock portfolio. The CA Bvf Inc owns 16360538 shares. Oncothyreon Inc is 9.06% of the manager’s US portfolio.
Business Profile

Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen. The Company is developing preclinical product candidates in oncology, and certain rare diseases, using its protocell technology. It also collaborates with partners to discover and develop additional product candidates. The Company is developing a series of orally active Chk1 inhibitors in collaboration with Sentinel Oncology Ltd. The Company is focusing its activities with protocells on the delivery of mini-circle DNA or mRNA to produce proteins intracellularly in specifically targeted organs or cells. It is collaborating with Adimab LLC for the discovery of antibodies against undisclosed immunotherapy targets in oncology.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

The institutional sentiment decreased to 0.47 in Q3 2015. Its down 1.17, from 1.64 in 2015Q2. The ratio worsened, as 22 funds sold all Oncothyreon Inc (USA) shares owned while 42 reduced positions. 9 funds bought stakes while 21 increased positions. They now own 55.19 million shares or 1.99% less from 56.32 million shares in 2015Q2.

Bvf Inc Il holds 9.06% of its portfolio in Oncothyreon Inc (USA) for 16.36 million shares. Venbio Select Advisor Llc owns 5.51 million shares or 3.92% of their US portfolio. Moreover, Perkins Capital Management Inc has 1.19% invested in the company for 390,650 shares. The California-based Ecor1 Capital Llc has invested 1.18% in the stock. Redmile Group Llc, a California-based fund reported 3.61 million shares.

Analysts await Oncothyreon Inc (USA) (NASDAQ:ONTY) to reports earnings on March, 8. They expect $-0.09 earnings per share, down 12.50% or $0.01 from last year’s $-0.08 per share. After $-0.08 actual earnings per share reported by Oncothyreon Inc (USA) for the previous quarter, Wall Street now forecasts 12.50% negative EPS growth.